Company / Capital Expenditures
Moleculin Biotech, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$13.0K
FY2025
5-year range
$13.0K / $376.0K
FY2021-FY2025
Trend
-89.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $0 in FY2016 to $417,000 in FY2019.
Based on SEC 10-K filings.
$13,000 in FY2025 with a 5-year CAGR of -24.2%.
Declined from $67,000 to $13,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -11.9%
- 5-Year CAGR
- -24.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -24.2%, indicating a declining trend.
- In FY2025, capital expenditures decreased 89.5% year-over-year.
- Peak capital expenditures was recorded in FY2019.
- Lowest capital expenditures in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.0K | -89.5% |
| FY2024 | $124.0K | +85.1% |
| FY2023 | $67.0K | +252.6% |
| FY2022 | $19.0K | -94.9% |
| FY2021 | $376.0K | +623.1% |
| FY2020 | $52.0K | -87.5% |
| FY2019 | $417.0K | +1389.3% |
| FY2018 | $28.0K | +33.3% |
| FY2017 | $21.0K | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026